Merck & Co Inc at Citi BioPharma Conference (Virtual) Transcript
Good morning, or good afternoon to those of you in Europe.
This is Andrew Baum from Citi's global health care team, delighted to introduce our next session.
As you'll see from the roster of familiar faces above me, we have the management from Merck, namely Roy Baynes, the Chief Development Officer and Chief Medical Officer; and Peter Dannenbaum, the Head of Investor Relations. Many thanks, both of you, for joining us.
We've got about 45 minutes. I want to keep it a free-flowing discussion. (Operator Instructions)
Questions & Answers
So maybe a leading question, to start. A criticism that we get from investors, and obviously we've been a very long-term bull of immuno-oncology and Merck in particular, is that there is too much dependency on KEYTRUDA. The durability of KEYTRUDA is questioned in terms of biosimilar entrants. And more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
